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The WHO European Region has been declared polio-free
since 2002. By 2010, inactivated polio vaccine (IPV) was the
only polio vaccine in use in the EU/EEA for the primary
vaccination of children. A systematic review of the literature
on polio seroprevalence studies, complemented by the
analysis of available vaccine coverage data, has been carried
out with the aim of assessing the level of protection against
polio in the European population. A total of 52 studies, with
data from 14 out of the 31 EU/EEA countries, were included in
the analysis. This systematic review shows that, overall,
seroprevalence for PV1 and PV3 is high in most countries,
although seroimmunity gaps have been detected in several
birth cohorts. In particular, relatively low immunity status was
found in some countries for individuals born in the 60’s and
70’s. Discrepancies between reported vaccination coverage
and immunity levels have been also highlighted. Countries
should make sure that their population is being vaccinated
for polio to reduce the risk of local poliovirus transmission in
case of importation. Moreover, assessing immunity status
should be priority for those traveling to areas where wild
polioviruses are still circulating.
Introduction
The WHO European Region has been declared polio-free
since 2002.1 As a consequence, those member states of the
European Union (EU) and the European Economic Area (EEA)
that still included oral polio vaccine (OPV) in the childhood
immunization schedule progressively switched to an inactivated
polio vaccine (IPV) schedule.2 By 2010, IPV was the only polio
vaccine in use in the EU/EEA for the primary vaccination of
children, while OPV is still in use in Poland as a booster dose
at 6 years of age.3 This was in line with the WHO global strat-
egy to limit the circulation of vaccine-derived poliovirus once
the circulation of wild-type poliovirus (WPV) had been
stopped.2 Out of the 3 serotypes, only wild poliovirus 1 and 3
still circulate globally; the most recent wild poliovirus 3 detec-
tion was in November 2012, while poliovirus 1 is the predomi-
nant circulating wild strain.4
The uncontrolled transmission of polio virus in Pakistan,
as well as the increased international spread during the low
season in 2014, led the Director-General of the WHO to
declare, in May 2014, the international spread of WPV in
2014 a Public Health Emergency of International Concern
(PHEIC), in accordance with the International Health Regu-
lations (IHR).5
The likelihood of WPV transmission and disease after impor-
tation into EU countries is considered low thanks to effective vac-
cination programmes and very good hygiene levels.6
Nevertheless, the changed global situation together with the pres-
ence of pockets of under-immunized population groups provides
grounds for questioning this assumption.
As shown in the past and, most recently, by the detection of
wild poliovirus type 1 (WPV1) from sewage samples collected in
May 2013 in Israel and in March 2014 in Brazil, importation of
poliovirus to polio-free regions may happen at any time as long
as poliovirus is circulating in the world.
Knowledge of the immunity status of the population is a nec-
essary component for assessing the risk of WPV transmission
after importation into EU. In order to describe the susceptibility
to polio in the EU, we conducted a systematic review of the liter-
ature on polio seroprevalence studies and complemented that
information by estimating the number of susceptible individuals
using available vaccine coverage data.
Methods
Search strategy and selection criteria
PubMed, Embase.com and Cochrane Library have been
searched up to 31st May 2014 for studies on the seroepidemiol-
ogy of polio. The concepts of polio and seroprevalence, serology,
immunity and prevalence were combined. Free-text/natural
vocabulary (i.e. keywords) and medical subject heading (MeSH
and Emtree) terms were used. No language or geographical
restrictions were applied in the search string. Reference lists of
retrieved articles were also reviewed.
References retrieved were uploaded to Endnote X6 (Thomas
Reuter, 2012. Endnote X6.0.1. Philadelphia). Three investigators
(D.N., A.M., P.C.S.) systematically screened search results by
title and abstract. Exclusion criteria were: studies performed in
non-EU/EEA or European overseas countries and territories, not
polio, not in humans, no seroprevalence, clinical trial, outbreak
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situation, missing information on age of study population, only
data on immigrants and study performed before vaccination era.
Full text articles of selected abstracts were retrieved and data
extracted (D.N.) if they met the criteria. Discrepancies were
resolved by consensus.
Data extraction and measurement of the outcome
Information on country, region, study population, study year,
randomization, sample size, measurement tool, age, seropreva-
lence rates per serotype per age group and vaccine schedule was
extracted. Data on infants less than one year were excluded due
to potential confusion with maternal antibodies.
To measure immunity to polio, WHO recommends using a
micro neutralization test with Sabin strains of poliovirus types 1
(PV1), 2 (PV2), and 3 (PV3) as challenge samples 7. In particu-
lar, the strains PV1-LSc/2ab, PV2-P712 and PV3-Leon as strains
from which the Sabin oral vaccine were derived, and the strains
PV1-Mahoney-Brunhilde, PV2-MEF-1 and PV3-Saukett as
strains from which the Salk inactivated vaccine were derived.8,9
The cut off titer recommended by the WHO to demonstrate
poliovirus immunity in humans is 1:8,10 however less conserva-
tive titres were also included (e.g. 1:2). We define high immu-
nity when at least 90% of the population is immune to polio.2
Data analysis
Seroprevalence by year of birth, starting from the onset of vac-
cination programmes in each country, has been calculated. To do
so, age groups were recoded to birth cohorts by subtracting the
age of the participants from the study year. When the study year
was unknown, year of publication minus 1 was used. After recal-
culating the birth cohorts, the median (and range if more than
one study was available) seroprevalence per decade was calculated
by polio type and country. Some papers reported data from pop-
ulations samples tested in different periods; in such cases the dif-
ferent evaluations are displayed as different studies (Table 1).
Since the main goal of the study was to assess the risk for WPV
reintroduction in Europe and wild type PV2 is no longer circu-
lating,11 only data for PV1 and PV3 are presented.
To obtain coverage data on 3 doses of polio vaccine the Cen-
tralized Information System for Infectious Diseases (CISID) has
been used (data available from 1980).12 Median coverage by
decade and country has been calculated. Only countries for
which we had data on seroprevalence were included. As vaccine
effectiveness for 3 doses of either IPV or OPV is close to
100%,13–15 vaccination coverage was considered a good proxy of
seroprevalence, hence vaccine coverage data were not adjusted.
Results
A total of 52 studies, with data from 14 out of the 31 EU/EEA
countries, were included 16-67; these 14 countries account for
around 80% of the EU/EEA population.68The flow diagram of
the study selection process can be found in Figure 1.
All included studies used the (micro) neutralization test for
determining immunity to poliovirus; 20 four studies used the cut
off titer recommended by the WHO (1:8) and 6 used a more
conservative cut off (5 1:10, and one 1:16) (Table 1). Con-
cerning the Sabin strains of poliovirus used as challenge samples,
4 studies used the 3 Sabin strains corresponding with OPV
(PV1-LSc/2ab, PV2-P712, PV3-Leon); 15 studies used the 3
inactivated polio virus strains (PV1-Mahoney-Brunhilde, PV2-
MEF-1, PV3-Saukett); 3 studies used a combination of these
strains and for 30 studies it was unknown; 22 studies did not
report any information on cut off titer.
Seroprevalence for PV1 (Fig. 2) in the studies ranged from
57.8% in Belgium to 100% in Bulgaria and the Czech Republic.
Most of the studies show PV1 seroprevalence over 80% for all
the time periods available. However, for individuals born in the
sixties and seventies, some countries reported lower PV1 sero-
prevalence values (when several estimates were available, the low-
est value has been reported) (Belgium 57.8% (60s); Germany
62.4% (60s); Italy 65% (60s) and UK 64.4% (70s)).
Concerning PV3 (Fig. 3), seroprevalence ranged from 61.4%
in Belgium to 100% in Bulgaria and Czech Republic. Overall,
seroprevalence for this serotype is over 80% in most of the stud-
ies. Also for PV3, some countries reported low seroprevalence
values in individuals born in the sixties, seventies and eighties
(Belgium 61.4% (60s); Germany 47.5% (80s); Italy 65.5%
(60s–90s); Portugal 63.5% (80s) and UK 48.6% (60s)).
Data on polio vaccine coverage (Figs. 2 and 3) ranged from
25% in the eighties in Portugal to 99.2% in the nineties in Swe-
den. Overall, reported vaccine coverage was very high, with all
countries being over 90% after the nineties. In some countries
like Germany, Italy and the UK, differences were found in the
estimates produced by the different studies available (Table 2,
Figs. 1 and 2).
In most countries where both seroprevalence and coverage
data was available for the last decades, values were similar. For
PV1, there is a slight difference of around 10% in Bulgaria and
Germany in the nineties (Fig. 2). For PV3, differences between
both data sources can be seen in Bulgaria, Germany, Greece
-both in the eighties and the ninetiesand for the last decade in
the Netherlands (Fig. 3). Italy, Spain and Portugal reported vac-
cination coverage levels below the measured sero-immunity.
Discussion
This systematic review shows that, overall, seroprevalence for
PV1 and PV3 is high in most countries and periods where data
are available, although several birth cohorts showed seroimmun-
ity gaps in specific populations. On average, Czech Republic,
Italy, and Sweden showed immunity rates above 90% for almost
all birth cohorts to all types of polio, while Belgium, Croatia,
Greece, and the United Kingdom showed immunity rates below
that threshold for almost all birth cohorts to all types of polio.
On the other hand, the epidemiological evidence supported by
good quality surveillance show, also in these countries, that gen-
eral immunity levels have been sufficient to stop wild polioviruses
circulation. France, Lithuania, The Netherlands and Spain
showed some gaps over time in the immunization status of the
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population. Data from Germany, Italy and the UK showed that
there were considerable differences in immunity within the coun-
try. This difference was especially visible in Germany as former
East-Germany showed immunity rates 20–30% lower than for-
mer West-Germany. In Italy differences could be partially
explained by differences in implementing vaccination pro-
grammes as the regional health authorities are in charge of devel-
oping their own vaccination strategies.69
Relatively low immunity status was found in some countries
for individuals born in the 60’s and 70’s. For the interpretation
of these results, the different cut-offs used in the studies has to be
considered. Additionally, vaccination programmes started at dif-
ferent points in time, with different vaccines and catch up strate-
gies. Therefore it is very hard to assess the situation at the
beginning of the polio vaccination campaigns. As an example, in
some countries, like the former East-Germany, higher coverage
levels were obtained only when IPV was replaced by OPV in the
60’s. Assuming these populations have not been exposed to the
virus other than through vaccination, currently the seropreva-
lence would be below 80% for these individuals, aged 35 to
55 years, even without considering any waning immunity effect.
Such evidence should not be considered as implying on immedi-
ate epidemic risk, given the generally high levels of sanitation and
hygiene in the EU, but should be taken into consideration
especially for individual protection of those in that age group
traveling in areas where wild polioviruses are still circulating.
Reported vaccination coverage for 3 doses of polio for the last
30 years is generally very high. However, in countries where both
reported coverage and seroprevalence data were available, these
results were not always supported with equally high seropreva-
lence levels. This is the case for Bulgaria, Germany, and Greece.
These differences could be due either to low potency of the vac-
cine used (primary vaccine failure) or to difficulties in vaccination
coverage assessment in the countries, which would lead to inaccu-
rate data reported to CISID. Vaccination coverage assessment is
essential to monitor the performance of immunization systems in
order to evaluate the progress toward the achievement of goals
for controlling and/or eliminating vaccine preventable diseases.
Last but not least, it is important to mention that a good overall
coverage in a region or country does not guarantee the absence of
transmission should polio virus be introduced. Areas or groups
with low coverage can still exist. Being able to identify these
groups would help implementing specific immunization
campaigns.
This study presents some limitations. Many studies in the sys-
tematic review used cut off titres different from the ones recom-
mended by WHO. Using cut off titres below 1:8 (22 studies)
could lead to an overestimation of the population’s immunity to
Figure 1. Flow diagram of the study selection process.
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polio and, conversely, titres over 1:8 (6 studies) could lead to an
underestimation of the population’s immunity. Considering this,
the overall estimate of seroprevalence in this review is more likely
to be biased toward overestimation of the EU population’s
immunity. In addition, the current analysis did not take into
consideration any decline of immunity over the time, since data
are presented by birth cohort independently from when the sero-
prevalence was assessed. The sampling methods quality varied
and was not optimal for some studies, so sampled subjects
were not always representative of the country’s population.
Figure 2. Median Polio 1 antibodies seroprevalence and 3 doses poliovaccine coverage by decade and EU/EEA Country. Vertical axis: Percentage (%);
Horizontal axis: decade; Gray line: median Polio 1 antibodies seroprevalence (%); Black line: median 3 doses poliovaccine coverage (%); Light gray square:
range of the median Polio 1 antibodies seroprevalence (%).
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Additionally, only 14 out of
the 31 countries included in
the EU/EEA are represented
in the systematic review and as
such the reported data may
not represent the whole situa-
tion in the EU/EEA. On the
other hand, these 14 countries
account for around 80% of
the EU/EEA population.
Finally, no specific data on
recognized vulnerable popula-
tions were reported in the
studies, thus reported esti-
mates are referred to the gen-
eral population only.
Conclusions
The aim of the present
review was to assess the
immunological protection
against WPV in the EU pop-
ulation, which is one of the
components of the risk of
WPV reintroduction in the
European Region. Vaccine-
derived polioviruses (VDVP)
have not been taken into
consideration and therefore
PV1 and PV3 only have been
presented as they are the only
WPV circulating strains.
Even though the immunity
status of the EU/EEA popu-
lation is high overall, this
study points to some elements that could theoretically allow
local transmission following introduction of poliovirus. In
fact, immunological protection of EU/EEA population is
patchy. Seroimmunity to polio was below the herd threshold
in some countries, especially in relation to PV3. A gap in polio
immunity in some EU/EEA countries for individuals currently
aged 35 to 55 years was found. Additionally, discrepancies
between vaccination coverage and seroprevalence levels in
some countries are worth further investigation and clarifica-
tion; reported immunization coverage in children and young
adults may be overestimated in some countries, so leaving a
higher number than might be assumed of susceptible in these
young ages. Conversely it is important to underline that a
population’s immunity is only one determinant of poliovirus
Figure 3. Median Polio 3 anti-
bodies seroprevalence and 3
doses poliovaccine coverage by
decade and EU/EEA Country. Ver-
tical axis: Percentage (%); Hori-
zontal axis: decade; Gray line:
median Polio 3 antibodies sero-
prevalence (%); Black line:
median 3 doses poliovaccine
coverage (%); Light gray square:
range of the median Polio 3 anti-
bodies seroprevalence (%).
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circulation in the community. Environmental factors and the
overall hygiene level are crucial aspects for assessing the risk of
polio re-introduction in the EU/EEA. The overall good levels
of hygiene and sanitation in the EU/EEA countries represent
an important risk mitigation factor. In conclusion, even in the
presence of immunity gap, the overall protection of the EU/
EEA population against the risk of wild polioviruses should be
considered good.
Recommendations
Countries should make sure that their population is being vac-
cinated for polio to reduce the risk of poliovirus transmission in
case of importation. Moreover, assessing immunity status should
be priority for those traveling to areas where wild polioviruses are
still circulating. One or more IPV booster doses, according to the
national recommendations, should be considered in such cases.
Increase in vaccination coverage should go hand to hand with
proper vaccination monitoring. For some countries no seropreva-
lence studies were available (or not recent ones), therefore further
research would be advised to get a better overview of the EU/
EEA situation. Monitoring of hard to reach populations is also
needed in order to assess the susceptibility of polio in these
groups. Finally, it would be advised to comply with the WHO
guidelines to enable more accurate comparison between studies.
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